Investors in GILD should be encouraged by its entry into oncology. I saw its booth at AACL 2015, and its 16-18 page handouts regarding approval of ZYDELIG for treatment of FL and SLL[albeit with boxed safety warning] and potential, off-label indication in CLL for relapsed patients treated with rituximab.[same boxed safety warning] There is additional pipeline.
My V-Pak estimate for 1Q15 is $350-450M (#msg-111336181), although I won’t be shocked if the figure is only $250M, due to slowness in clearing reimbursement for Medicaid and other public-payer patients.
Perhaps more important, I’m not expecting ABBV to provide more detailed V-Pak guidance for the full year 2015 than it already has with its statement of a $3B+ year-end annualized run rate. (I do expect more detailed full-year guidance after the 2Q15 results.)
15:30 - 16:00 Abstract LP27: ACH-3422, A NOVEL NUCLEOTIDE PRODRUG INHIBITOR OF HCV NS5B POLYMERASE (View abstract) Presenter: Edward Gane
15:30 - 16:00 Abstract LP06: SUSTAINED VIROLOGIC RESPONSE AFTER ACH-3102 AND SOFOSBUVIR TREATMENT FOR 8 OR 6 WEEKS: A PHASE 2 “PROXY” STUDY (View abstract) Presenter: Edward Gane